A 32-year-old woman from Mumbai with secondary infertility (1 child 5 years ago, now trying for 2 years) presents for evaluation. Cycles regular (26–28 days), normal flow. BMI 28 kg/m². Husband's semen analysis normal. Serum FSH 7 mIU/mL, LH 6 mIU/mL, prolactin normal. Transvaginal ultrasound shows normal ovaries, no polycystic pattern. Hysterosalpingography shows patent tubes. Diagnostic laparoscopy reveals mild endometriosis (stage II, American Society for Reproductive Medicine). She is counselled for ovulation induction. Which agent is most appropriate for this patient?

Explanation

## Clinical Context This patient has: - **Secondary infertility** with regular ovulatory cycles (ovulation is likely occurring) - **Stage II (mild) endometriosis** on diagnostic laparoscopy - Normal FSH/LH, normal ovarian reserve - Normal male factor, patent tubes - BMI 28 kg/m² (overweight range) **Key Point:** The stem explicitly asks for the most appropriate **ovulation induction agent**. In a patient with mild endometriosis (Stage I–II), regular cycles, and no other identifiable cause of infertility, the first-line ovulation induction agent is **letrozole**, not gonadotropins. ## Why Letrozole is First-Line in Endometriosis-Associated Infertility | Feature | Letrozole | Clomiphene Citrate | Gonadotropins | |---------|-----------|-------------------|---------------| | **Mechanism** | Aromatase inhibitor → ↓ estrogen → ↑ FSH | SERM → blocks estrogen feedback → ↑ FSH | Direct FSH stimulation | | **Endometriosis context** | **Preferred** — reduces local estrogen (anti-estrogenic at endometriosis implants) | Less preferred — estrogenic effect may stimulate endometriosis | Reserved for failed oral agents or IVF | | **Endometrial receptivity** | Better (no anti-estrogenic effect on endometrium) | Impaired (anti-estrogenic on endometrium) | Good | | **Multiple pregnancy risk** | Low | Low–moderate | Higher | | **OHSS risk** | Minimal | Minimal | Moderate | | **Monitoring** | Minimal | Minimal | Frequent ultrasound + E2 | **Clinical Pearl (per ESHRE Endometriosis Guidelines & Barbieri/Hornstein):** In women with Stage I–II endometriosis and infertility, **letrozole + IUI** is the recommended first-line ovulation induction strategy. Letrozole is preferred over clomiphene citrate because: 1. It reduces local estrogen production, which may suppress endometriosis implants 2. It does not have the anti-estrogenic effect on the endometrium seen with clomiphene 3. Studies (including Mitwally & Casper) show superior pregnancy rates with letrozole vs. CC in endometriosis-associated infertility ## Why Not the Other Options? - **Clomiphene citrate 100 mg (Option C):** Starting dose is typically 50 mg; 100 mg is a higher dose. More importantly, CC has anti-estrogenic effects on the endometrium, reducing receptivity. Letrozole is preferred over CC in endometriosis per current evidence. - **Tamoxifen 20 mg (Option B):** A SERM occasionally used for ovulation induction but not a standard first-line agent; rarely used in modern practice and not preferred in endometriosis. - **Gonadotropins 150 IU (Option D):** Appropriate for controlled ovarian hyperstimulation (COH) with IUI/IVF, but this represents a **second-line or escalation** strategy after failure of oral agents, or when proceeding directly to IVF. The stem asks for the most appropriate ovulation induction agent — gonadotropins are not first-line for simple ovulation induction in Stage II endometriosis with regular cycles. **High-Yield:** Endometriosis (Stage I–II) + infertility + ovulation induction = **Letrozole** (first-line oral agent, preferred over clomiphene due to favorable endometrial and anti-estrogenic-at-implant profile). **Reference:** ESHRE Endometriosis Guideline 2022; Barbieri RL, Hornstein MD — "Endometriosis and Infertility," UpToDate; Mitwally MF & Casper RF, *Fertility and Sterility* 2001.